Good overall response rates in clinical trials have recently prompted FDA breakthrough approval of the irreversible BTK inhibitor Ibrutinib (PCI-32765) for the treatment of relapsed MCL and CLL [7, 9]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.